Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIM1 | P11309 | 12/20 | 0.46 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.45 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.44 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | PIM2 | Q9P1W9 | 4/20 | 0.44 |
| ▸ | PIM3 | Q86V86 | 3/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 2/20 | 0.41 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.40 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.40 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12435456 | 0.88 | CYP2A6 (0.43) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL11929454 | 0.88 | CYP2A6 (0.43) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL12435522 | 0.83 | PIM1 (0.39) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL2218828 | 0.81 | PIM1 (0.41) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL12435706 | 0.81 | PIM1 (0.38) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL11929453 | 0.80 | CYP2A6 (0.45) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL11929456 | 0.79 | SLC2A1 (0.44) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL12435549 | 0.78 | PDPK1 (0.39) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL12435501 | 0.77 | NPC1 (0.42) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 | |
| SCHEMBL12435525 | 0.76 | MAPK10 (0.35) | PIM1CYP2A6CYP2E1CYP2C9CYP2B6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | PIM1 2969/4885CYP2A6 705/4885CYP2E1 1598/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.